Market Closed -
OTC Markets
04:00:00 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
17.95
USD
|
+0.62%
|
|
+0.34%
|
+60.27%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
195.8
|
176.6
|
232.4
|
439.7
|
393.3
|
635.1
|
-
|
-
|
Enterprise Value (EV)
1 |
195.8
|
176.6
|
232.4
|
439.7
|
393.3
|
635.1
|
635.1
|
635.1
|
P/E ratio
|
778
x
|
-52.8
x
|
-12.5
x
|
-28.9
x
|
-14.9
x
|
-33
x
|
31.9
x
|
10.2
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
3.83
x
|
3.61
x
|
3.21
x
|
4.96
x
|
3.02
x
|
3.5
x
|
2.55
x
|
2.1
x
|
EV / Revenue
|
3.83
x
|
3.61
x
|
3.21
x
|
4.96
x
|
3.02
x
|
3.5
x
|
2.55
x
|
2.1
x
|
EV / EBITDA
|
42.7
x
|
30.9
x
|
11.9
x
|
33.8
x
|
14
x
|
17.9
x
|
8.57
x
|
5.21
x
|
EV / FCF
|
-
|
-
|
70.5
x
|
-
|
-
|
423
x
|
18.5
x
|
-
|
FCF Yield
|
-
|
-
|
1.42%
|
-
|
-
|
0.24%
|
5.42%
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
25,173
|
25,746
|
26,903
|
29,790
|
35,118
|
35,382
|
-
|
-
|
Reference price
2 |
7.780
|
6.860
|
8.640
|
14.76
|
11.20
|
17.95
|
17.95
|
17.95
|
Announcement Date
|
3/13/20
|
3/8/21
|
3/10/22
|
3/23/23
|
3/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
51.16
|
48.87
|
72.48
|
88.6
|
130.2
|
181.3
|
248.6
|
303
|
EBITDA
1 |
4.583
|
5.715
|
19.5
|
13.02
|
28.12
|
35.43
|
74.12
|
121.9
|
EBIT
1 |
-4.803
|
0.385
|
1.614
|
1.919
|
0.431
|
3.44
|
44.12
|
93.55
|
Operating Margin
|
-9.39%
|
0.79%
|
2.23%
|
2.17%
|
0.33%
|
1.9%
|
17.74%
|
30.88%
|
Earnings before Tax (EBT)
1 |
-0.125
|
-3.415
|
-17.87
|
-14.01
|
-23.71
|
-17.84
|
27.62
|
83.12
|
Net income
1 |
0.168
|
-3.357
|
-18.48
|
-14.09
|
-24.41
|
-19.19
|
21.79
|
78.14
|
Net margin
|
0.33%
|
-6.87%
|
-25.5%
|
-15.9%
|
-18.75%
|
-10.58%
|
8.76%
|
25.79%
|
EPS
2 |
0.0100
|
-0.1300
|
-0.6900
|
-0.5100
|
-0.7500
|
-0.5433
|
0.5633
|
1.760
|
Free Cash Flow
1 |
-
|
-
|
3.296
|
-
|
-
|
1.5
|
34.4
|
-
|
FCF margin
|
-
|
-
|
4.55%
|
-
|
-
|
0.83%
|
13.83%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
16.91%
|
-
|
-
|
4.23%
|
46.41%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
157.9%
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/13/20
|
3/8/21
|
3/10/22
|
3/23/23
|
3/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
20.19
|
22.12
|
23.32
|
22.82
|
20.33
|
26.1
|
33.47
|
34.26
|
36.36
|
34.59
|
42.42
|
49.03
|
56.19
|
53.9
|
61.02
|
EBITDA
1 |
4.599
|
4.94
|
4.505
|
-1.021
|
1.089
|
5.342
|
11
|
9.209
|
2.563
|
0.227
|
5.91
|
11.43
|
16.75
|
10.84
|
16.76
|
EBIT
1 |
-1.755
|
2.101
|
1.69
|
-0.094
|
-1.778
|
1.21
|
2.352
|
1.744
|
-4.875
|
-6.928
|
-1.683
|
4.407
|
8.027
|
3.665
|
9.195
|
Operating Margin
|
-8.69%
|
9.5%
|
7.25%
|
-0.41%
|
-8.75%
|
4.64%
|
7.03%
|
5.09%
|
-13.41%
|
-20.03%
|
-3.97%
|
8.99%
|
14.28%
|
6.8%
|
15.07%
|
Earnings before Tax (EBT)
1 |
-7.285
|
-2.438
|
-6.199
|
-6.429
|
1.055
|
-6.931
|
-4.244
|
-2.852
|
-9.683
|
-13.56
|
-6.973
|
-0.8467
|
2.82
|
-1.12
|
4.445
|
Net income
1 |
-7.418
|
-2.438
|
-6.239
|
-6.464
|
1.055
|
-6.643
|
-4.229
|
-4.391
|
-9.148
|
-13.56
|
-6.51
|
-1.243
|
2.117
|
-1.285
|
3.025
|
Net margin
|
-36.74%
|
-11.02%
|
-26.75%
|
-28.32%
|
5.19%
|
-25.45%
|
-12.64%
|
-12.81%
|
-25.16%
|
-39.22%
|
-15.35%
|
-2.54%
|
3.77%
|
-2.38%
|
4.96%
|
EPS
2 |
-0.2700
|
-0.0900
|
-0.2300
|
-0.2400
|
0.0400
|
-0.2200
|
-0.1400
|
-0.1300
|
-0.2600
|
-0.3800
|
-0.2000
|
-0.0550
|
0.0875
|
-0.0350
|
0.0850
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/22
|
5/5/22
|
8/9/22
|
11/14/22
|
3/23/23
|
5/11/23
|
8/9/23
|
11/13/23
|
3/19/24
|
5/13/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
3.3
|
-
|
-
|
1.5
|
34.4
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
1.79
|
2.6
|
-
|
0.4
|
0.75
|
-
|
Capex / Sales
|
-
|
-
|
2.46%
|
2.93%
|
-
|
0.22%
|
0.3%
|
-
|
Announcement Date
|
3/13/20
|
3/8/21
|
3/10/22
|
3/23/23
|
3/19/24
|
-
|
-
|
-
|
Last Close Price
17.95
USD Average target price
26.9
USD Spread / Average Target +49.86% Consensus |
1st Jan change
|
Capi.
|
---|
| +60.27% | 635M | | +40.73% | 739B | | +32.83% | 598B | | -6.30% | 353B | | +15.15% | 318B | | +4.05% | 285B | | +15.00% | 240B | | -5.52% | 206B | | +6.17% | 164B | | -0.45% | 162B |
Other Pharmaceuticals
|